var data={"title":"Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/414090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Patient drug information&quot;</a> and <a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074407\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Voluven</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074408\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Volulyte;</li>\n      <li>Voluven</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074412\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Plasma Volume Expander, Colloid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074444\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Plasma volume expansion:</b> IV infusion: May administer up to 50 mL/kg/day (or up to 3500 mL per day in a 70 kg patient); may administer repetitively over several days. <b>Note:</b> With severe dehydration, administer crystalloid first. Daily dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in the critically ill including patients with sepsis, those with preexisting renal dysfunction or receiving dialysis, those with preexisting bleeding disorders or those with intracranial bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074443\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Plasma volume expansion:</b> IV infusion: <b>Note:</b> With severe dehydration, administer crystalloid first. Daily dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in the critically ill including patients with sepsis, those with preexisting renal dysfunction or receiving dialysis, those with preexisting bleeding disorders or those with intracranial bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &le;12 years and Adolescents: May administer  up to 50 mL/kg/day (or up to 3500 mL per day in a 70 kg patient); may administer repetitively over several days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mean daily dose &plusmn; SD in pediatric clinical trials:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;2 years: 16 &plusmn; 9 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2-12 years: 36 &plusmn; 11 mL/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074445\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074446\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid use in patients with preexisting renal dysfunction. Use is contraindicated in oliguric/anuric renal failure unrelated to hypovolemia or patients receiving dialysis. Discontinue use at the first sign of renal injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074447\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling; use is contraindicated in severe liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074457\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voluven: 6% (500 mL) [dehp free, latex free, pvc free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074410\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13940442\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion, premixed in isotonic electrolyte solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Volulyte: 6% (250 mL, 500 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074450\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer IV only; may be administered via infusion pump or pressure infusion. Infuse the initial 10-20 mL slowly while observing for possible anaphylactoid reaction; have epinephrine and resuscitative equipment available. If administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Do not use if crystalline precipitate forms or is turbid deep brown. Change IV tubing at least every 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074415\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Blood volume expander used in treatment and prevention of hypovolemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50876134\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Voluven may be confused with VoLumen</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074423\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (dose dependent; may be delayed), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Increased serum amylase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, coagulation time increased, decreased clotting factors, decreased hematocrit, prolonged prothrombin time, wound hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anaphylactoid reaction, anaphylaxis, bradycardia, bronchospasm, circulatory shock, flu-like symptoms, hypersensitivity reaction, hypotension, non-cardiogenic pulmonary edema, shock, tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074418\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hydroxyethyl starch or any component of the formulation; renal failure with oliguria or anuria (not related to hypovolemia); dialysis; any fluid overload condition (eg, pulmonary edema, congestive heart failure); severe hypernatremia; severe hyperchloremia; patients with intracranial bleeding; critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy; severe liver disease; preexisting coagulation or bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Volulyte only: Severe hyperkalemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074419\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Anaphylactoid reactions (eg, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, noncardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Monitor the coagulation status in patients undergoing open heart surgery in association with cardiopulmonary bypass. HES solutions have been associated with excess bleeding in these patients. Discontinue use of HES at the first sign of coagulopathy. Use is contraindicated in patients with preexisting coagulation or bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young patients, elderly patients); use is contraindicated in heart failure or any preexisting condition where volume overload is a potential concern. Adjust the dosage in patients with preexisting cardiac dysfunction. Avoid use in patients with preexisting renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemodilution: Large volumes may cause a reduction in hematocrit, coagulation factors and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Monitor liver function at baseline and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Monitor liver function at baseline and periodically during treatment. Use is contraindicated in patients with severe liver disease; may result in further reduction of coagulation factors, increasing the risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with preexisting renal impairment; fluid status including urine output should be monitored closely; discontinue use at the first sign of renal injury. Use is contraindicated with oliguria or anuria unrelated to hypovolemia or patients receiving hemodialysis.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Critically-ill patients: <b>[US Boxed Warning]: HES solutions have been associated with mortality and renal injury requiring renal replacement therapy in critically-ill patients, including patients with sepsis; avoid use in critically-ill adult patients, including those with sepsis.</b> Use should also be avoided in patients admitted to the ICU (Brunkhorst, 2008; Perel, 2011; Perner, 2012; Zarychanski, 2009). The Society of Critical Care Medicine (SCCM) also recommends against the use of HES solutions for fluid resuscitation of severe sepsis and septic shock; crystalloids (eg, sodium chloride, Ringer&rsquo;s lactate) are recommended as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement (Rhodes 2017). If used in patients who are not critically ill, avoid use in patients with preexisting renal dysfunction and discontinue use at the first sign of renal injury. Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor renal function in all patients for at least 90 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not a substitute for red blood cells or coagulation factors. Severely dehydrated patients should be infused with a sufficient volume of crystalloid solution initially, prior to consideration of tetrastarch administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory test interference: May cause temporarily elevated serum amylase levels and interfere with pancreatitis diagnosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300129\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10140508\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8728&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: Tetrastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074416\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079782\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917133\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tetrastarch is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tetrastarch to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074453\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, capillary refill time, CVP, RAP, MAP; if pulmonary artery catheter in place, monitor cardiac index, PCWP, SVR, and PVR; hemoglobin, coagulation parameters, renal function (continue to monitor for at least 90 days after administration), liver function, urine output, acid-base balance </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074432\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces plasma volume expansion by virtue of its highly colloidal starch structure </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074434\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &ge;6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 5.9 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Molecules &gt;50,000 daltons are metabolized by plasma &alpha;-amylase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (smaller hydroxyethyl starch molecules [&lt;50,000 daltons] unchanged, metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: 31.4 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322845\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Voluven Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6-0.9% (500 mL): $61.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962021\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tetrahes (ID, KR);</li>\n      <li>TetraHES (TZ);</li>\n      <li>Tetraspan (DK, EE, HK, NO, PH, TW);</li>\n      <li>Volulyte (CZ, DK);</li>\n      <li>Voluven (AE, AR, AT, AU, BH, CH, CL, CN, CR, CU, CY, DO, EE, ES, FI, FR, GR, GT, HK, HN, HR, ID, IL, IS, JP, KR, LT, LU, LV, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TW, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/18184958/pubmed\" target=\"_blank\" id=\"18184958\">18184958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chong Sung K, Kum Suk P, Mi Ja Y, et al, &quot;Effects of Intravascular Volume Therapy Using Hydroxyethyl Starch (130/0.4) on Post-Operative Bleeding and Transfusion Requirements in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial,&quot; <i>Acta Anaesthesiol Scand</i>, 2006, 50(1):108-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/16451158/pubmed\" target=\"_blank\" id=\"16451158\">16451158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanart C, Khalife M, De Vill&eacute; A, et al, &quot;Perioperative Volume Replacement in Children Undergoing Cardiac Surgery: Albumin Versus Hydroxyethyl Starch 130/0.4,&quot; <i>Crit Care Med</i>, 2009, 37(2):696-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/19114887/pubmed\" target=\"_blank\" id=\"19114887\">19114887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lochbuhler H, Galli C, and Hagemann H, &quot;Hydroxylethyl Starch HES 130/0.4 in Paediatric Surgery: Results on an Explorative, Controlled, Multicenter Safety Study,&quot; <i>Crit Care</i>, 2003, 7(2 Suppl):107.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osthaus WA, Witt L, Johanning K, et al, &quot;Equal Effects of Gelatin and Hydroxyethyl Starch (6% HES 130/0.42) on Modified Thrombelastography in Children,&quot; <i>Acta Anaesthesiol Scand</i>, 2009, 53(3):305-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/19173690/pubmed\" target=\"_blank\" id=\"19173690\">19173690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perel P and Roberts I, &ldquo;Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo; <i>Cochrane Database Syst Rev</i>, 2012, 6:CD000567.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/22696320/pubmed\" target=\"_blank\" id=\"22696320\">22696320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 versus Ringer&rsquo;s Acetate in Severe Sepsis [published correction appears in <i>N Engl J Med</i>. 2012;367(5):481]. <i>N Engl J Med</i>. 2012;367(2):124-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/22738085/pubmed\" target=\"_blank\" id=\"22738085\">22738085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo; <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/22323076/pubmed\" target=\"_blank\" id=\"22323076\">22323076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&uuml;mpelmann R, Kretz FJ, G&auml;bler R, et al, &ldquo;Hydroxyethyl Starch 130/0.42/6:1 for Perioperative Plasma Volume Replacement in Children: Preliminary Results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS),&rdquo; <i>Paediatr Anaesth</i>, 2008, 18(10):929-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/18647272/pubmed\" target=\"_blank\" id=\"18647272\">18647272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voluven (tetrastarch) [prescribing information]. Lake Forest, IL: Hospira, Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voluven (tetrastarch) [product monograph]. Ontario, Canada: Fresenius Kabi Canada; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Volulyte (tetrastarch) [product monograph]. Ontario, Canada: Fresenius Kabi Canada; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witt L, Osthaus WA, J&uuml;ttner B, et al, &quot;Alteration of Anion Gap and Strong Ion Difference Caused by Hydroxyethyl Starch 6% (130/0.42) and Gelatin 4% in Children,&quot; <i>Paediatr Anaesth</i>, 2008, 18(10):934-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/18811828/pubmed\" target=\"_blank\" id=\"18811828\">18811828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo; <b>ATTENTION:</b> The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release. <i>Open Med</i>, 2009, 3(4):e196-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information/abstract-text/21688756/pubmed\" target=\"_blank\" id=\"21688756\">21688756</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8728 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10074407\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10074408\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10074412\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F10074444\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F10074443\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F10074445\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10074446\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10074447\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F10074457\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F10074410\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13940442\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10074450\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10074415\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50876134\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10074423\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10074418\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10074419\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300129\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F10140508\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F10074416\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14079782\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17917133\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10074453\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10074432\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F10074434\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322845\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962021\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8728|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-patient-drug-information\" class=\"drug drug_patient\">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Patient drug information</a></li><li><a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information\" class=\"drug drug_pediatric\">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information</a></li></ul></div></div>","javascript":null}